Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism

1972 ◽  
Vol 2 (4) ◽  
pp. 406-413 ◽  
Author(s):  
R. H. S. Mindham ◽  
R. Gaind ◽  
B. H. Anstee ◽  
Lorna Rimmer

SynopsisA double-blind comparison was made of the effects of amantadine hydrochloride, orphenadrine hydrochloride, and placebo in the control of the effects on the extrapyramidal nervous system of fluphenazine decanoate. Patients were assessed with regard to the main symptoms of Parkinsonism, the leading clinical signs, performance in walking, writing and squeezing, changes in mood, and unwanted effects of medication. Neither of the pharmacologically active substances was superior to placebo. Attention is drawn to the paucity of evidence for the effectiveness of anti-cholinergic drugs in both Parkinson's disease and in drug-induced Parkinsonism. The special difficulties in performing trials of substances used in relieving the unwanted effects of other drugs are discussed in relationship to defects in methodology in both this and earlier trials. The findings of the present study are not conclusive but show a clear need for further research in this field. The possible theoretical and practical importance of such research is discussed.

1982 ◽  
Vol 27 (7) ◽  
pp. 593-596 ◽  
Author(s):  
N. Russell ◽  
J. Landmark ◽  
H. Merskey ◽  
T. Turpin

A double-blind comparison of fluspirilene and fluphenazine decanoate in 28 schizophrenic patients over six months showed equal improvement and the same incidence of side-effects in each group of patients. It would be expected from the literature that a better ratio of therapeutic to side-effects would appear with fluspirilene than with fluphenazine. The absence of such an effect in this study may be attributable to an initial lack of familiarity by the investigators with the use of fluspirilene, indicating an important potential variable in the comparison of a new drug with an established one.


Sign in / Sign up

Export Citation Format

Share Document